

# **Mitral Valve Disease Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment Type (Repair, Replacement, Cardiac Resynchronization Therapy, Therapeutics), By Indication (Stenosis, Prolapse, Regurgitation), By End-User (Hospitals, Ambulatory Surgical Centers, Others), By Region & Competition, 2020-2030F**

<https://marketpublishers.com/r/MAF6A7EB171AEN.html>

Date: February 2025

Pages: 180

Price: US\$ 4,500.00 (Single User License)

ID: MAF6A7EB171AEN

## **Abstracts**

The global Mitral Valve Disease (MVD) market was valued at USD 3.25 billion in 2024 and is projected to experience significant growth, with a compound annual growth rate (CAGR) of 8.85% from 2024 to 2030. The MVD market is rapidly expanding within the broader cardiovascular devices and treatments sector. Conditions like mitral valve regurgitation (MR) and mitral valve stenosis (MS) are prevalent worldwide, creating substantial opportunities for market development. Key drivers of this growth include an aging population, the increasing prevalence of cardiovascular diseases, continuous advancements in medical technologies, and rising demand for minimally invasive treatment options.

This market is expected to experience strong growth, fueled by innovations in diagnostics and treatments, alongside a growing preference for minimally invasive procedures. With a focus on improving patient outcomes, expanding access to care, and integrating cutting-edge technologies, the MVD market is poised for robust expansion. As awareness of mitral valve disease increases, particularly in aging populations, the demand for effective and accessible treatment options is also on the rise, further contributing to market growth.

### **Key Market Drivers**

## Growing Prevalence of Mitral Valve Disease (MVD)

The rising prevalence of mitral valve disease (MVD) is a primary factor driving the growth of the global MVD market. As MVD becomes more common worldwide, the demand for diagnostic services, treatment options, and healthcare infrastructure tailored to this condition is escalating. Alongside aging, modern lifestyle factors such as obesity, hypertension, diabetes, and smoking are contributing to the higher incidence of MVD. These lifestyle-related conditions are increasingly prevalent, particularly in emerging economies, driving the number of MVD cases.

Obesity is a major global concern, with one in eight individuals living with obesity as of 2022. The prevalence of adult obesity has more than doubled since 1990, with over 890 million adults affected. Hypertension is also widespread, with 1.28 billion adults aged 30 to 79 suffering from the condition, particularly in low- and middle-income countries. This growing incidence of hypertension and obesity directly impacts the prevalence of MVD, placing additional demand on healthcare systems.

The global increase in life expectancy further contributes to the rising incidence of MVD. As people live longer, the likelihood of developing MVD increases, resulting in a larger patient population requiring long-term treatment and management. The global life expectancy is projected to rise from 73.6 years in 2022 to 78.1 years by 2050, which presents both challenges and opportunities for healthcare businesses in addressing the needs of an aging population.

Additionally, as cardiovascular diseases (CVDs) continue to be the leading cause of global mortality, MVD is emerging as a significant contributor to heart failure and related complications. This escalating burden highlights the urgent need for effective diagnostic, treatment, and management solutions for MVD, thus driving market demand.

## Key Market Challenges

### High Treatment Costs

A major challenge for the growth of the Global Mitral Valve Disease Market is the high cost associated with diagnosis and treatment. Mitral valve diseases often necessitate complex surgical interventions or the implantation of prosthetic valves, which can be prohibitively expensive. Traditional open-heart surgeries and minimally invasive techniques such as transcatheter mitral valve repair (TMVR) both incur significant costs,

including surgeon fees, operating room charges, and the cost of prosthetic devices.

Post-operative care and recovery for MVD patients also contribute to high healthcare costs, which include follow-up appointments, medications, and cardiac rehabilitation. In certain regions, inadequate insurance coverage for MVD treatments further compounds the financial burden, potentially deterring patients from seeking timely medical attention and hindering market growth.

## Key Market Trends

### Rise of Minimally Invasive Procedures

One of the prominent trends in the Global Mitral Valve Disease Market is the increasing adoption of minimally invasive procedures for diagnosing and treating MVD. Traditional open-heart surgery has long been the standard approach, but advances in medical technology have introduced less invasive options, such as transcatheter mitral valve repair (TMVR) and transcatheter mitral valve replacement (TMVR).

Minimally invasive procedures offer several advantages, including smaller incisions, reduced pain, shorter hospital stays, and faster recovery times. These benefits are driving greater patient demand for minimally invasive options, particularly among high-risk or elderly patients who may not be candidates for open-heart surgery. As healthcare professionals gain expertise in performing these procedures, their adoption is expected to continue to rise.

## Key Market Players

Corcym UK Limited

Abbott Laboratories Inc.

Zydus Lifesciences Limited

Medtronic plc

Edwards Lifesciences Corporation

Affluent Medical SA

ShockWave Medical, Inc.

Valcare Medical

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

#### Report Scope:

This report segments the Global Mitral Valve Disease Market into the following categories, along with the industry trends:

#### Mitral Valve Disease Market by Treatment Type:

Repair

Replacement

Cardiac Resynchronization Therapy

Therapeutics

#### Mitral Valve Disease Market by Indication:

Stenosis

Prolapse

Regurgitation

#### Mitral Valve Disease Market by End-User:

Hospitals

Ambulatory Surgical Centers

Others

#### Mitral Valve Disease Market by Region:

North America: United States, Canada, Mexico

Europe: France, United Kingdom, Italy, Germany, Spain

Asia-Pacific: China, India, Japan, Australia, South Korea

South America: Brazil, Argentina, Colombia

Middle East & Africa: South Africa, Saudi Arabia, UAE

#### Competitive Landscape

This section provides a detailed analysis of major companies in the Global Mitral Valve Disease Market.

#### Available Customizations:

TechSci Research offers tailored customizations to the Global Mitral Valve Disease market report, providing specific data and insights according to a company's needs. Customization options include:

Detailed analysis and profiling of additional market players (up to five).

## Contents

### **1. PRODUCT OVERVIEW**

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### **2. RESEARCH METHODOLOGY**

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### **3. EXECUTIVE SUMMARY**

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### **4. VOICE OF CUSTOMER**

### **5. MITRAL VALVE DISEASE MARKET OUTLOOK**

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Treatment Type (Repair, Replacement, Cardiac Resynchronization Therapy, Therapeutics)
  - 5.2.2. By Indication (Stenosis, Prolapse, Regurgitation)
  - 5.2.3. By End-User (Hospitals, Ambulatory Surgical Centers, Others)

- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map

## **6. NORTH AMERICA MITRAL VALVE DISEASE MARKET OUTLOOK**

- 6.1. Market Size & Forecast
  - 6.1.1. By Value
- 6.2. Market Share & Forecast
  - 6.2.1. By Treatment Type
  - 6.2.2. By Indication
  - 6.2.3. By End-User
  - 6.2.4. By Country
- 6.3. North America: Country Analysis
  - 6.3.1. United States Mitral Valve Disease Market Outlook
    - 6.3.1.1. Market Size & Forecast
      - 6.3.1.1.1. By Value
    - 6.3.1.2. Market Share & Forecast
      - 6.3.1.2.1. By Treatment Type
      - 6.3.1.2.2. By Indication
      - 6.3.1.2.3. By End-User
  - 6.3.2. Canada Mitral Valve Disease Market Outlook
    - 6.3.2.1. Market Size & Forecast
      - 6.3.2.1.1. By Value
    - 6.3.2.2. Market Share & Forecast
      - 6.3.2.2.1. By Treatment Type
      - 6.3.2.2.2. By Indication
      - 6.3.2.2.3. By End-User
  - 6.3.3. Mexico Mitral Valve Disease Market Outlook
    - 6.3.3.1. Market Size & Forecast
      - 6.3.3.1.1. By Value
    - 6.3.3.2. Market Share & Forecast
      - 6.3.3.2.1. By Treatment Type
      - 6.3.3.2.2. By Indication
      - 6.3.3.2.3. By End-User

## **7. EUROPE MITRAL VALVE DISEASE MARKET OUTLOOK**

- 7.1. Market Size & Forecast

- 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Treatment Type
  - 7.2.2. By Indication
  - 7.2.3. By End-User
  - 7.2.4. By Country
- 7.3. Europe: Country Analysis
  - 7.3.1. Germany Mitral Valve Disease Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Treatment Type
      - 7.3.1.2.2. By Indication
      - 7.3.1.2.3. By End-User
  - 7.3.2. United Kingdom Mitral Valve Disease Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Treatment Type
      - 7.3.2.2.2. By Indication
      - 7.3.2.2.3. By End-User
  - 7.3.3. Italy Mitral Valve Disease Market Outlook
    - 7.3.3.1. Market Size & Forecast
      - 7.3.3.1.1. By Value
    - 7.3.3.2. Market Share & Forecast
      - 7.3.3.2.1. By Treatment Type
      - 7.3.3.2.2. By Indication
      - 7.3.3.2.3. By End-User
  - 7.3.4. France Mitral Valve Disease Market Outlook
    - 7.3.4.1. Market Size & Forecast
      - 7.3.4.1.1. By Value
    - 7.3.4.2. Market Share & Forecast
      - 7.3.4.2.1. By Treatment Type
      - 7.3.4.2.2. By Indication
      - 7.3.4.2.3. By End-User
  - 7.3.5. Spain Mitral Valve Disease Market Outlook
    - 7.3.5.1. Market Size & Forecast
      - 7.3.5.1.1. By Value
    - 7.3.5.2. Market Share & Forecast



7.3.5.2.1. By Treatment Type

7.3.5.2.2. By Indication

7.3.5.2.3. By End-User

## **8. ASIA-PACIFIC MITRAL VALVE DISEASE MARKET OUTLOOK**

### **8.1. Market Size & Forecast**

8.1.1. By Value

### **8.2. Market Share & Forecast**

8.2.1. By Treatment Type

8.2.2. By Indication

8.2.3. By End-User

8.2.4. By Country

### **8.3. Asia-Pacific: Country Analysis**

#### **8.3.1. China Mitral Valve Disease Market Outlook**

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Treatment Type

8.3.1.2.2. By Indication

8.3.1.2.3. By End-User

#### **8.3.2. India Mitral Valve Disease Market Outlook**

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Treatment Type

8.3.2.2.2. By Indication

8.3.2.2.3. By End-User

#### **8.3.3. Japan Mitral Valve Disease Market Outlook**

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Treatment Type

8.3.3.2.2. By Indication

8.3.3.2.3. By End-User

#### **8.3.4. South Korea Mitral Valve Disease Market Outlook**

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

- 8.3.4.2.1. By Treatment Type
- 8.3.4.2.2. By Indication
- 8.3.4.2.3. By End-User
- 8.3.5. Australia Mitral Valve Disease Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Treatment Type
    - 8.3.5.2.2. By Indication
    - 8.3.5.2.3. By End-User

## **9. SOUTH AMERICA MITRAL VALVE DISEASE MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Treatment Type
  - 9.2.2. By Indication
  - 9.2.3. By End-User
  - 9.2.4. By Country
- 9.3. South America: Country Analysis
  - 9.3.1. Brazil Mitral Valve Disease Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Treatment Type
      - 9.3.1.2.2. By Indication
      - 9.3.1.2.3. By End-User
  - 9.3.2. Argentina Mitral Valve Disease Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Treatment Type
      - 9.3.2.2.2. By Indication
      - 9.3.2.2.3. By End-User
  - 9.3.3. Colombia Mitral Valve Disease Market Outlook
    - 9.3.3.1. Market Size & Forecast
      - 9.3.3.1.1. By Value
    - 9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Treatment Type

9.3.3.2.2. By Indication

9.3.3.2.3. By End-User

## **10. MIDDLE EAST AND AFRICA MITRAL VALVE DISEASE MARKET OUTLOOK**

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Treatment Type

10.2.2. By Indication

10.2.3. By End-User

10.2.4. By Country

10.3. MEA: Country Analysis

10.3.1. South Africa Mitral Valve Disease Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Treatment Type

10.3.1.2.2. By Indication

10.3.1.2.3. By End-User

10.3.2. Saudi Arabia Mitral Valve Disease Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Treatment Type

10.3.2.2.2. By Indication

10.3.2.2.3. By End-User

10.3.3. UAE Mitral Valve Disease Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Treatment Type

10.3.3.2.2. By Indication

10.3.3.2.3. By End-User

## **11. MARKET DYNAMICS**

11.1. Drivers

## 11.2. Challenges

## 12. MARKET TRENDS & DEVELOPMENTS

### 12.1. Recent Developments

### 12.2. Product Launches

### 12.3. Mergers & Acquisitions

## 13. GLOBAL MITRAL VALVE DISEASE MARKET: SWOT ANALYSIS

## 14. PORTER'S FIVE FORCES ANALYSIS

## 15. COMPETITIVE LANDSCAPE

### 15.1. Corcym UK Limited

#### 15.1.1. Business Overview

#### 15.1.2. Product & Service Offerings

#### 15.1.3. Recent Developments

#### 15.1.4. Financials (If Listed)

#### 15.1.5. Key Personnel

#### 15.1.6. SWOT Analysis

### 15.2. Abbott Laboratories Inc

### 15.3. Zydus Lifesciences Limited

### 15.4. Medtronic plc

### 15.5. Edwards Lifesciences Corporation

### 15.6. Affluent Medical SA

### 15.7. ShockWave Medical, Inc.

### 15.8. Valcare Medical

### 15.9. Pfizer Inc

### 15.10. Teva Pharmaceutical Industries Ltd.

## 16. STRATEGIC RECOMMENDATIONS

## 17. ABOUT US & DISCLAIMER

## I would like to order

Product name: Mitral Valve Disease Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment Type (Repair, Replacement, Cardiac Resynchronization Therapy, Therapeutics), By Indication (Stenosis, Prolapse, Regurgitation), By End-User (Hospitals, Ambulatory Surgical Centers, Others), By Region & Competition, 2020-2030F

Product link: <https://marketpublishers.com/r/MAF6A7EB171AEN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MAF6A7EB171AEN.html>